Ariana’s AI provides evidence for 3 years clinical efficacy of ANAVEX®2-73 Alzheimer’s targeted therapy @CTAD2018
Precision medicine approach using Ariana’s AI KEM® shows that a small data rich open label clinical study of 32 well-characterized patients may be sufficient to identify strong biomarker hypothesis identifying patients with the highest chance of benefiting from the drug. […]
Ariana Pharma helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial
Ariana Pharma helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial. […]
Gastric Cancer: Artificial Intelligence helps identify novel single biomarkers to guide targeted precision medicine
Gastric Cancer: Ariana and academic collaborators from the Gastro Glyco Explorer consortium identify a novel single marker for Microsatellite instability (MSI), a distinct molecular subtype of gastric cancer. […]
Artificial Intelligence enables first biomarker driven precision medicine therapy against Alzheimer
Ariana Pharma helps ANAVEX® demonstrate efficacy of its Alzheimer’s therapy in phase 2a clinical trial. […]